Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;279(10):4787-4792.
doi: 10.1007/s00405-022-07264-3. Epub 2022 Jan 20.

Real life safety of systemic steroids for sudden sensorineural hearing loss: a chart review

Nir Halevy  1   2 , Bshara Elias  1   2 , Shahaf Shilo  1   2 , Nidal Muhanna  1   2 , Ophir Handzel  1   2 , Yahav Oron  1   2 , Rani Abu Eta  1   2 , Omer J Ungar  3   4
Affiliations

Real life safety of systemic steroids for sudden sensorineural hearing loss: a chart review

Nir Halevy et al. Eur Arch Otorhinolaryngol. 2022 Oct.

Abstract

Objectives: To report adverse events (AEs) associated with systemic steroid treatment in idiopathic sudden sensorineural hearing loss (ISSNHL).

Material and methods: A retrospective chart review of consecutive patients newly diagnosed with ISSNHL necessitating systemic steroidal treatment was conducted from 1/2017 to 2/2021. Blood pressure (BP) was monitored three times daily and morning fasting glucose was monitored once daily during treatment. An AE was defined as a fasting blood glucose level > 160 mg/dl, systolic BP > 80 mmHg, and diastolic BP > 100 mmHg.

Results: In total, 143 patients were enrolled [69 (48%) males and 74 (52%) females] of whom 29 (20%) had diabetes mellitus (DM) and 46 (32%) had hypertension (HTN). The cohort's median age (interquartile range) was 58 (37-69) years. Fifty-three patients (37%) did not complete the oral steroidal treatment due to any AE (glycemic or hypertensive). Background DM highly correlated with increased risk of a glycemic event (0.59 vs. 0.13 for diabetic and non-diabetic patients, respectively, P < 0.001). HTN correlated significantly with increased risk of an overall AE (0.54 vs. 0.29 for hypertensive and non-hypertensive patients, respectively, P = 0.001). Neither pre-treatment BP nor glucose level predicted the risk of an AE (P = 0.310 and 0.521, respectively).

Conclusions: AEs due to systemic steroidal treatment are common among ISSNHL patients. Demographic and baseline values cannot predict the risk of AEs which can occur throughout the entire duration of treatment. Patients with DM and HTN are at the greatest risk of AEs. Tight blood glucose and BP monitoring are recommended during treatment.

Keywords: Idiopathic sudden sensorineural hearing loss; Systemic steroids.

PubMed Disclaimer

References

    1. Wilson WR, Byl FM, Laird N (1980) The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch Otolaryngol 106(12):772–776 - DOI
    1. Chen CY, Halpin C, Rauch SD (2003) Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol Neurotol 24(5):728–733 - DOI
    1. Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, Hollingsworth DB, Kelley DM, Kmucha ST, MoonisPoling GGL (2019) Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg 161(1):1–45 - DOI
    1. Buchman AL (2001) Side effects of corticosteroid therapy. J Clin Gastroenterol 33(4):289–294 - DOI
    1. Aimoni C, Bianchini C, Borin M, Ciorba A, Fellin R, Martini A, Scanelli G, Volpato S (2010) Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: a case-control study. Audiol Neurotol 15(2):111–115 - DOI

LinkOut - more resources